Lynx1 Capital Management »

Entrada Therapeutics shares owned by Lynx1 Capital Management

Quarter-by-quarter ownership of Entrada Therapeutics (TRDA) shares owned by Lynx1 Capital Management from 13F filings

Historical chart of Lynx1 Capital Management investment in Entrada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Entrada Therapeutics held by Lynx1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Entrada Therapeutics by Lynx1 Capital Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $531k 52k 10.28

More positions owned by Lynx1 Capital Management

Stoke Therapeutics (STOK)
Gh Research Ordinary Shares (GHRS)
Cullinan Oncology (CGEM)
Denali Therapeutics (DNLI)
C4 Therapeutics Com Stk (CCCC)
Xencor (XNCR)
Immatics SHS (IMTX)
Tscan Therapeutics (TCRX)
Passage Bio Com New (PASG)
Korro Bio (KRRO)
Precision Biosciences Com New (DTIL)
Neuphoria Therapeutics (NEUP)
Agios Pharmaceuticals (AGIO)
Cg Oncology (CGON)
Arrowhead Pharmaceuticals (ARWR)

View all positions for Lynx1 Capital Management

Top funds holding Entrada Therapeutics

Baker Bros. Advisors
MPM Asset Management
5AM Venture Management
BlackRock
TCG Crossover Management
Vanguard Group
Wellington Management Company
Millennium Management
StepStone
Geode Capital Management
State Street Corporation
Jacobs Levy Equity Management
Citadel Advisors
Acadian Asset Management
Dimensional Fund Advisors

View all funds holding Entrada Therapeutics